Prostate Cancer

Phase 2 trial of antagonist in hormone-dependent prostate cancer launched

Published in Cancer Weekly, May 10th, 2005

Spectrum Pharmaceuticals, Inc. (SPPI) announced the launch of a phase 2 trial to evaluate the safety and efficacy of SPI-153 as a treatment for patients with hormone-dependent prostate cancer.

The multi-center phase 2 trial is designed to evaluate the effects of SPI-153 on hormonal levels, in particular testosterone, as well as objective anti-tumor effects. The trial will be conducted in Europe with the collaboration of AEterna Zentaris Inc. (AEZ), Spectrum's licensor of SPI-153 (D-63153).

Prostate cancer is the second leading cause of cancer deaths in men and occurs when a malignant tumor forms in the tissue of the prostate. According to figures...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry